Published in Nat Rev Clin Oncol on August 23, 2011
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med (2013) 8.89
Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med (2012) 2.00
HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol (2012) 1.67
How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn (2012) 1.66
Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting. Br J Cancer (2013) 1.51
Therapeutic target database update 2014: a resource for targeted therapeutics. Nucleic Acids Res (2013) 1.31
Drug repositioning for personalized medicine. Genome Med (2012) 1.24
The impact of probiotics and prebiotics on the immune system. Nat Rev Immunol (2012) 1.19
Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-approval validation study of the companion diagnostic test for vemurafenib. PLoS One (2013) 1.05
Addressing human variability in next-generation human health risk assessments of environmental chemicals. Environ Health Perspect (2012) 1.00
Validation of dynamic contrast-enhanced ultrasound in predicting outcomes of antiangiogenic therapy for solid tumors: the French multicenter support for innovative and expensive techniques study. Invest Radiol (2014) 0.99
Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol (2016) 0.99
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. Expert Rev Mol Diagn (2012) 0.97
Tissue banking, bioinformatics, and electronic medical records: the front-end requirements for personalized medicine. J Oncol (2013) 0.95
A new regulatory road-map for Alzheimer's disease drug development. Curr Alzheimer Res (2014) 0.92
Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group. Front Oncol (2013) 0.90
Transparency of reporting in molecular diagnostics. Int J Mol Sci (2013) 0.89
FuseFISH: robust detection of transcribed gene fusions in single cells. Cell Rep (2013) 0.89
Prognostic value of LIPC in non-small cell lung carcinoma. Cell Cycle (2013) 0.88
Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer. PLoS One (2014) 0.87
Mutations in the hedgehog pathway genes SMO and PTCH1 in human gastric tumors. PLoS One (2013) 0.87
The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC. Oncotarget (2015) 0.86
Omics Profiling in Precision Oncology. Mol Cell Proteomics (2016) 0.85
Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res (2013) 0.85
Glutathione S-conjugates as prodrugs to target drug-resistant tumors. Front Pharmacol (2014) 0.84
DDX3, a potential target for cancer treatment. Mol Cancer (2015) 0.83
Commentary on Hey and Kimmelman. Clin Trials (2015) 0.83
Mathematical and statistical modeling in cancer systems biology. Front Physiol (2012) 0.81
The Marker State Space (MSS) method for classifying clinical samples. PLoS One (2013) 0.81
High-Density Dielectrophoretic Microwell Array for Detection, Capture, and Single-Cell Analysis of Rare Tumor Cells in Peripheral Blood. PLoS One (2015) 0.81
Relevance of deep learning to facilitate the diagnosis of HER2 status in breast cancer. Sci Rep (2017) 0.80
ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma. Oncotarget (2015) 0.79
Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474. Cancer Sci (2015) 0.79
Creative trial design in RA: optimizing patient outcomes. Nat Rev Rheumatol (2013) 0.78
Derivation of a fifteen gene prognostic panel for six cancers. Sci Rep (2015) 0.78
On the Slow Diffusion of Point-of-Care Systems in Therapeutic Drug Monitoring. Front Bioeng Biotechnol (2015) 0.78
A novel flow cytometry-based cell capture platform for the detection, capture and molecular characterization of rare tumor cells in blood. J Transl Med (2014) 0.78
Identifying predictive markers for personalized treatment selection. Biometrics (2016) 0.78
Contextualised urinary biomarker analysis facilitates diagnosis of paediatric obstructive sleep apnoea. Sleep Med (2014) 0.77
Mathematical framework for activity-based cancer biomarkers. Proc Natl Acad Sci U S A (2015) 0.77
Biological markers: Tailoring treatment and trials to prognosis. Nat Rev Clin Oncol (2013) 0.77
Biomarkers to guide clinical therapeutics in rheumatology? Curr Opin Rheumatol (2016) 0.76
Challenges in pharmacogenetics. Eur J Clin Pharmacol (2013) 0.76
Optimized Protocol for Quantitative Multiple Reaction Monitoring-Based Proteomic Analysis of Formalin-Fixed, Paraffin-Embedded Tissues. J Proteome Res (2016) 0.76
Inhibiting the system xC(-)/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nat Commun (2017) 0.75
Biomarkers for cystic fibrosis drug development. J Cyst Fibros (2016) 0.75
Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers. Trends Cardiovasc Med (2016) 0.75
Prognostic value of LIPC in non-small cell lung carcinoma. Cell Cycle (2013) 0.75
The Impact of Receiving Predictive Genetic Information about Lynch Syndrome on Individual Colonoscopy and Smoking Behaviors. Cancer Epidemiol Biomarkers Prev (2016) 0.75
Targeting Negative Surface Charges of Cancer Cells by Multifunctional Nanoprobes. Theranostics (2016) 0.75
Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients. Dis Markers (2017) 0.75
Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. Ther Adv Med Oncol (2015) 0.75
A precision medicine approach to a patient with unresolved pain following orthopedic surgery: a case report. J Med Case Rep (2017) 0.75
Letter in response to "Our HER2 is same as yours". Transl Gastroenterol Hepatol (2016) 0.75
A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics. Front Genet (2016) 0.75
Short-term spheroid culture of primary colorectal cancer cells as an in vitro model for personalizing cancer medicine. PLoS One (2017) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol (2009) 21.94
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med (2007) 12.73
Triple-negative breast cancer. N Engl J Med (2010) 11.39
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2010) 9.77
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol (2004) 9.73
EGFR antagonists in cancer treatment. N Engl J Med (2008) 9.68
The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer (2005) 8.99
Melanoma. N Engl J Med (2006) 8.80
Targeted cancer therapy. Nature (2004) 7.81
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer (2006) 7.53
Chronic myeloid leukemia. N Engl J Med (1999) 7.11
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
The PARP superfamily. Bioessays (2004) 6.14
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol (2009) 5.64
Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med (2011) 4.94
Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature (2007) 4.70
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res (2007) 4.45
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol (2007) 4.19
Breast and ovarian cancer. N Engl J Med (2003) 3.84
A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol (2008) 3.59
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer (2007) 3.36
Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem (2007) 3.05
The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer (2010) 3.03
Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer (2009) 2.63
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol (2007) 2.50
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol (2006) 2.48
Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res (2011) 2.42
Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol (2011) 2.40
Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res (2007) 2.25
Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. Oncology (Williston Park) (2010) 2.10
Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev (2003) 2.02
Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene (2003) 2.02
The HER2 testing conundrum. Nat Biotechnol (2010) 2.00
Retinoic acid receptors and cancers. Annu Rev Nutr (2004) 1.93
Personalized medicine in oncology: the future is now. Nat Rev Drug Discov (2010) 1.91
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell (2008) 1.90
The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nat Biotechnol (2006) 1.87
Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res (2007) 1.71
Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer (2006) 1.66
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer (2006) 1.65
PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res (2007) 1.60
HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc (2002) 1.59
Evolving treatment of advanced colon cancer. Annu Rev Med (2009) 1.56
Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol (2007) 1.54
Molecular targets for breast cancer therapy and prevention. Nat Med (2001) 1.50
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med (2009) 1.48
Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell (2000) 1.47
HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol (2009) 1.45
Oncogenic mutations as predictive factors in colorectal cancer. Oncogene (2010) 1.45
Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res (2004) 1.40
Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro Oncol (2010) 1.40
Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer. Oncogene (2009) 1.40
Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell (2009) 1.33
Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol (2007) 1.26
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci U S A (2010) 1.26
Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist (2007) 1.26
Dasatinib. Nat Rev Drug Discov (2006) 1.25
A personalized approach to cancer treatment: how biomarkers can help. Clin Chem (2008) 1.25
Cancer clinical trials--a chronic but curable crisis. N Engl J Med (2010) 1.24
Systematic review of HER2 breast cancer testing. Appl Immunohistochem Mol Morphol (2009) 1.04
Colorectal cancer in review: the role of the EGFR pathway. Expert Opin Investig Drugs (2010) 0.99
Evolution of biomarker qualification at the health authorities. Nat Biotechnol (2010) 0.97
Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective. Clin Pharmacol Ther (2009) 0.95
Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia. Leuk Res (2009) 0.94
Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol (2010) 0.93
Trastuzumab resistance: all roads lead to SRC. Nat Med (2011) 0.93
Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions. Oncologist (2010) 0.92
Imatinib: a review of its use in the management of gastrointestinal stromal tumours. Drugs (2007) 0.90
Optimizing treatment of chronic myeloid leukemia: a rational approach. Oncologist (2004) 0.88
Proteasome and HDAC: who's zooming who? Blood (2010) 0.86
Gene and drug matrix for personalized cancer therapy. Nat Rev Drug Discov (2010) 0.86
Imatinib treatment of metastatic GIST: don't stop (believing). Lancet Oncol (2010) 0.86
NICE and the challenge of cancer drugs. BMJ (2009) 0.85
Pharmacodynamics in cancer therapy. J Clin Oncol (1990) 0.83
Histone deacetylase inhibitors regulate retinoic acid receptor beta expression in neuroblastoma cells by both transcriptional and posttranscriptional mechanisms. Mol Endocrinol (2007) 0.83
Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy. Nat Rev Clin Oncol (2010) 0.83
The PML/RAR alpha fusion gene in the diagnosis and monitoring of acute promyelocytic leukemia. Haematologica (1995) 0.80
Market watch: emerging companion diagnostics for cancer drugs. Nat Rev Drug Discov (2010) 0.80
FDA holds court on post hoc data linking KRAS status to drug response. Nat Biotechnol (2009) 0.80
BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. PLoS Curr (2010) 0.79
Heterogeneity in chronic myeloid leukaemia dynamics during imatinib treatment: role of immune responses. Proc Biol Sci (2010) 0.79
Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML? Nat Rev Clin Oncol (2010) 0.77
Targeted therapies: Importance of patient selection for EGFR TKIs in lung cancer. Nat Rev Clin Oncol (2010) 0.77
Drug developers unveil strategies aimed at imatinib-resistant CML. J Natl Cancer Inst (2010) 0.77
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med (2004) 13.34
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet (2007) 9.23
Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet (2012) 6.25
Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat Genet (2010) 4.20
Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet (2012) 3.19
Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol (2013) 2.90
Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet (2009) 2.59
Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol (2011) 2.55
Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer. PLoS Genet (2011) 2.47
Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol (2010) 2.32
Open access chemical and clinical probes to support drug discovery. Nat Chem Biol (2009) 2.28
The challenge of cancer control in Africa. Nat Rev Cancer (2008) 1.71
Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol (2004) 1.54
Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol (2002) 1.52
A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology (2009) 1.46
Arginine methylation controls growth regulation by E2F-1. EMBO J (2012) 1.44
Defective mismatch repair in colon cancer: a prognostic or predictive biomarker? J Clin Oncol (2010) 1.34
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci U S A (2010) 1.26
Adjuvant chemotherapy for stage II colon cancer: less complicated than we thought. J Clin Oncol (2013) 1.26
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol (2009) 1.15
Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet (2005) 1.14
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol (2011) 1.12
Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway. Oncogene (2002) 1.08
Refinement of the associations between risk of colorectal cancer and polymorphisms on chromosomes 1q41 and 12q13.13. Hum Mol Genet (2011) 1.07
Capecitabine: have we got the dose right? Nat Clin Pract Oncol (2008) 1.02
Adjuvant chemotherapy for stage II colorectal cancer: the time is right! Nat Clin Pract Oncol (2005) 0.99
Nitroreductase: a prodrug-activating enzyme for cancer gene therapy. Clin Exp Pharmacol Physiol (2004) 0.99
A trial of adjuvant therapy in colorectal cancer: the VICTOR trial. Clin Colorectal Cancer (2003) 0.98
EnROL: a multicentre randomised trial of conventional versus laparoscopic surgery for colorectal cancer within an enhanced recovery programme. BMC Cancer (2012) 0.92
Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Ther (2002) 0.89
Challenges of cancer control in developing countries: current status and future perspective. Future Oncol (2011) 0.87
CB 1954: from the Walker tumor to NQO2 and VDEPT. Curr Pharm Des (2003) 0.86
Use of a phage display library to identify oligopeptides binding to the lumenal surface of polarized endothelium by ex vivo perfusion of human umbilical veins. J Drug Target (2003) 0.85
Colorectal cancer. Acta Oncol (2003) 0.85
Evolution of nonsurgical therapy for colorectal cancer. Nat Clin Pract Gastroenterol Hepatol (2009) 0.84
Tobacco: deadly in any form or disguise. Lancet (2006) 0.83
Roles of tetrahydrobiopterin in promoting tumor angiogenesis. Am J Pathol (2010) 0.82
Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vector. Int J Cancer (2003) 0.81
Ras as a target in cancer therapy. Crit Rev Oncol Hematol (2002) 0.80
Identification of oligopeptides binding to peritoneal tumors of gastric cancer. Cancer Sci (2006) 0.80
Immunotherapy for colorectal cancer. Expert Rev Anticancer Ther (2003) 0.80
Targeted therapies: Cetuximab plus chemotherapy in patients with advanced NSCLC. Nat Rev Clin Oncol (2009) 0.80
Regional hepatic chemotherapies in the treatment of colorectal cancer metastases to the liver. Semin Oncol (2010) 0.79
Gene therapy for colorectal cancer. Br Med Bull (2002) 0.79
The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database. Clin Colorectal Cancer (2013) 0.78
The nitroreductase/CB1954 enzyme-prodrug system. Methods Mol Med (2004) 0.78
Gene profiling in early stage disease. Cancer J (2010) 0.76
Quinone oxidoreductase-2-mediated prodrug cancer therapy. Sci Transl Med (2010) 0.76
Bacteriophage biopanning in human tumour biopsies to identify cancer-specific targeting ligands. J Drug Target (2007) 0.76
Health diplomacy: a new approach to the Muslim world? Global Health (2014) 0.75
Malignant peritoneal mesothelioma. Is there a new treatment? Rare Tumors (2009) 0.75
The emergence of 'omics for the management of colorectal cancer. Curr Opin Oncol (2011) 0.75
Identification of an oligopeptide binding to hepatocellular carcinoma. Oncology (2007) 0.75
Pharmacokinetic considerations in the use of anticancer drugs during pregnancy: challenges and new developments. Expert Opin Drug Metab Toxicol (2015) 0.75
Curbing tobacco's toll starts with the professionals: World No Tobacco Day. Lancet (2005) 0.75
EUFEPS report. Contribution of academic research to discovery and development of medicines: current status and future opportunities. Eur J Pharm Sci (2005) 0.75
Clinical experience with adenovirus in cancer therapy. Curr Opin Mol Ther (2002) 0.75